PharVision Advisers’s Eastman Chemical EMN Stock Holding History

PharVision Advisers’s Portfolio EMN Stock Details EMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,242	Closed	-$462K	–	310
2025 Q1	$462K	Buy	+5,242	New	+$495K	0.64%	19

Other funds holding EMN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

PharVision Advisers's EMN Position: Q2 2025 in Review

PharVision Advisers sold out of Eastman Chemical (EMN) in Q2 2025, closing a stake of 5,242 shares — an estimated $462K sold.

PharVision Advisers first reported a position in EMN in Q1 2025 and held it in 1 quarter. The position peaked at $462K in Q1 2025. 751 funds tracked by Wall St. Rank hold EMN as of Q2 2025.

PharVision Advisers reported no remaining Eastman Chemical position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 5,242 Eastman Chemical shares in Q2 2025, an estimated $462K.
PharVision Advisers first reported a position in Eastman Chemical in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Eastman Chemical position peaked at $462K in Q1 2025.
751 funds tracked by Wall St. Rank held Eastman Chemical as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.